The six-member life sciences practice at Bofill Mir Abogados has ‘extensive experience in legal and regulatory matters involving the life sciences industry’. The group is consistently mandated by both domestic and international clients from the pharmaceutical, cosmetics, medical devices, food, veterinary, agro-industrial, and hygiene sectors (among others). The team acts throughout the life sciences’ cycle, from establishing clients’ presence in Chile, to obtaining operational, marketing and sanitary authorisations. It also assists with product registrations, reviewing advertising, life sciences M&A, clinical studies implementation, and product-related labelling and technical literature. The department additionally handles public bids and other administrative procedures, as well as free competition and intellectual and industrial property; ongoing matters include assisting e-commerce technology company Mercado Libre with life sciences-related regulatory matters and advising German multinational pharmaceutical and biotechnology company, Bayer Group, on both regulatory and corporate matters. Practice head Andrea Abascal, a partner at Jara Del Favero Abogados until June 2023, is an administrative law expert who is particularly focused on regulated markets, including life sciences. At associate level, senior Anamaría Verdugo is a regulated markets and life sciences specialist; Andrés Sepúlveda's workload encompasses life sciences and public and regulatory law; and Juan Pablo Guzmán's career includes four years at relevant public agencies. Former partner Manuel Bernet and director Cristián Franetovic both departed the firm in August 2024.

Full-service legal giant Carey houses seasoned pharmacists and biochemists, in addition to highly-rated lawyers. The multidisciplinary life sciences group advises a range of clients from the healthcare, pharmaceutical, biotechnological, in vitro diagnostic medical device, telemedicine, food supplement, nutritional product and foodstuff sectors. It also has industry expertise in alcoholic beverages, animal feed, cosmetics, veterinary products and agrochemicals. Recent highlights include advising global biotechnology company Biogen on marketing authorisation applications for innovative drugs (through an accelerated procedure). The life sciences practice is co-led by Guillermo Carey, an adviser to major pharmaceutical and biotech innovation laboratories, whose track record includes significant life sciences and healthcare-related regulatory, product liability and IP matters; and Ignacio Gillmore, who focuses on regulatory, administrative, transactional, product liability, compliance and IP work. In the firm’s associate ranks, senior Cristina Busquets advises on the regulation of food, beverages and animal feed, including importation, commercialisation and advertising issues; Camila Suárez‘s career includes a three-year, part-time secondment to German multinational science and technology company Merck; and Mariana Guzmán and Isabel Cantillana are experienced regulatory, pharmaceutical, biotech and public law practitioners. Former senior José Santos Ossa left the firm in July 2025.

Home to ‘excellent lawyers who have extensive industry experience’, Albagli Zaliasnik's multidisciplinary regulatory and life sciences group is routinely sought out by major national and international pharmaceutical companies. The six-strong team, which comprises both lawyers and technical expert, covers biotechnology, pharmaceutical products, medical devices, cosmetics, food processing regulation, compliance, investigations, pharmaceutical litigation, technology transfer, public tenders, clinical trials and advertising. The firm also has a notable track record in pharmaceutical industry-related patent infringement cases, cancellation actions, and regulatory disputes; and regularly represents clients in administrative proceedings before Chile’s health, competition and IP authorities. Examples of mandates include advising multinational medical devices and healthcare company, Abbott, on the application of the public policy of bioequivalence to pharmaceutical products. Ariela Agosin leads the firm’s civil and arbitration, life sciences and public law and regulated markets groups; and IP, technology and data team head Eugenio Gormáz advises on life sciences, plant varieties, IP, cybersecurity, e-commerce, AI, and denominations of origin and geographical indications. Beyond the partnership, the experience of life sciences and competition director Dafne Guerra includes regulatory matters, consumer and advertising law, regulatory compliance, antitrust, patent litigation, health and safety regulation, and dispute resolution. At associate level Francisco Alarcón's wide-ranging expertise extends to the pharmaceutical industry.

The eight-member healthcare and life sciences practice at Baker McKenzie Chile routinely assists with filings before the national sanitary authority, registration cancellations, and obtaining licenses for manufacturing, selling, distributing and advertising products under local law. It also advises on public procurement regulation, along with clinical trials, access issues, medical device registrations, data exclusivity, adverse event reporting, administrative proceedings, recalls, disputes, and product acquisitions and transfers. The group is additionally able to leverage the firm’s global network of healthcare law specialists on behalf of major pharmaceutical clients. It assists US biotechnology and biomedical engineering firm Boston Scientific (on an ongoing basis) with matters involving the intersection between corporate regulatory and IP issues. Intellectual and industrial property expert Valentina Venturelli is also a specialist in life sciences and regulatory matters who acts on behalf of clients from the pharmaceutical, cosmetics, medical device, foodstuff and veterinary industries. Venturelli's experience includes advising on the import, distribution and commercialisation of products; sanitary regulations, clinical trials and scientific research. Primary support is provided by Fernando Castro, an adviser on pharmaceutical sector work, while corporate law associates Maria Elena Dörr and Martín Muller complete the group.

The life sciences practice at independent law firm Covarrubias is particularly experienced in IP and technological matters, including patents, plant varieties, trade marks, domain names, copyright, data protection, litigation and technology transfers. A ‘strategic ally for clients’ most important matters in Chile’, the team also covers the legal, regulatory and strategic side to product liability, investigations and enforcement actions. The four-member group further assists with the protection of clients’ life sciences-related rights during disputes (at both national and international levels); and on the regulatory front, the practice is mandated to advise on food, drugs, cosmetics and medical devices, as well as products requiring registration with Chile's regulatory agencies. Recent highlights for the group include assisting chemical company BASF with filing a patent application in Chile for fatty acid derivatives for the treatment of non-alcoholic steatohepatitis. Firm founder Arturo Covarrubias specialises in industrial property litigation involving the pharmaceutical, biotechnology, tissue paper, food, retail and telecoms sectors; and Matías Valenzuela is a biochemist who heads up the firm’s patent department. Former associate and litigation leader Diego Bilbao departed the firm in April 2024.

The IP branch of law firm Cariola Díez Pérez-Cotapos, Sargent & Krahn fields a sizeable team that covers life sciences-related regulatory matters and litigation, as well as data protection and clinical trial contracts. With ‘deep technical knowledge and sophisticated legal strategies’, the group is also highly rated for its expertise in bioequivalency and biosimilarity, in relation to chemical and biotech pharmaceutical products, along with life sciences-related IP rights. Other notable areas include public bidding processes for pharmaceutical product acquisitions, as well as advertising and promotional issues. The department additionally assists innovation departments from Chilean universities with national and international patent prosecutions and pharmaceutical product contracts. Patent group head Juan Pablo Egaña assists with both patent applications before the administrative authorities and the enforcement of industrial property rights before Chile’s courts of justice; and Cristian Barros M specialises in IP law and pharmaceutical regulation. At associate level, Juan Francisco Peralta‘s recent experience includes orphan drug-related mandates; Alejandra Varela‘s track record includes pharmaceutical patent appeals before the Industrial Property Court and healthcare sector regulatory matters; Macarena Correa’s experience includes advising on life sciences-related legislation; and Valentina Stark assists with the administrative law side to pharmaceutical regulatory issues.

The 15-strong team at Alessandri & Compañía Abogados is widely respected for its IP expertise. The group, which (in addition to lawyers) comprises patent technicians, engineers, chemists, biotechnologists and designers, is highly experienced in the processing of applications, as well as freedom-to-operate issues, prior art studies and drafting invention patents. The firm’s corporate team routinely works alongside its contractual, regulatory and antitrust colleagues on large public tenders for public hospitals and private healthcare institutions; and recent growth includes advising on public procurement system reforms and regulatory compliance strategies. Experienced in designing strategies for the global protection and licensing of innovation and patents, Santiago Ortúzar co-leads the firm’s intellectual and industrial property offering; while at associate level, senior Francisca Donoso and Francesca Bozzo are the names to note.

Fielding ‘a highly-qualified team of new-generation lawyers who are dedicated specifically to healthcare and law’, BACS Abogados' three-member group routinely acts in disputes involving health law and its track record including favourable rulings that prioritise patient welfare. The practice also covers disputes involving medical devices, product recalls and corporate accountability, and it is additionally experienced in securing access to high-cost therapies for patients with rare diseases. Life sciences specialist Esteban Barra Olivares is well known for advocating for constitutional remedies for expensive rare disease-related medicines; and providing key back up, María Victoria Miranda Polanco is a director in the firm’s health law team, whose recent experience includes significant healthcare and malpractice cases.